Mirabegron Palmitate Sustained-Release Injection for Obesity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for obesity and related metabolic disorders, such as β3-adrenergic receptor agonists like mirabegron, face challenges including low bioavailability, frequent dosing, and side effects, with no long-acting injectable formulations approved for obesity treatment in the USA, limiting their effectiveness and patient compliance.
Innovation Solution
Development of long-acting parenteral compositions of β3-adrenergic receptor agonists, specifically mirabegron or its palmitate ester, combined with pharmaceutically acceptable excipients, for extended or sustained release formulations suitable for intramuscular or subcutaneous administration, enhancing bioavailability and reducing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If oral dosage forms of β3-adrenergic receptor agonists are used, then the treatment can be administered conveniently, but the bioavailability is low and dosing frequency must be high
Solution Approach 1:
The patent transforms the drug from its original oral dosage form to a parenteral (injectable) formulation, fundamentally changing the route of administration parameter. This transformation enables direct delivery into the bloodstream, achieving near 100% bioavailability while maintaining ease of administration through simple injection protocols
2Reliability
If frequent dosing is used to maintain therapeutic levels, then therapeutic effectiveness is maintained, but patient compliance deteriorates
Solution Approach 1:
The patent employs sustained-release technology that maintains continuous therapeutic drug levels in the bloodstream over extended periods (weeks to months). This continuous delivery mechanism eliminates the need for frequent dosing while maintaining constant therapeutic effectiveness, thereby dramatically improving patient compliance
Solution Approach 2:
The formulation is designed to release the drug gradually over a predetermined extended period, effectively preparing and maintaining therapeutic levels in advance. This preliminary sustained-release mechanism ensures therapeutic effectiveness is continuously maintained without requiring frequent patient intervention
3Reliability
If high doses are administered to overcome low bioavailability, then therapeutic levels can be achieved, but toxicity and side effects increase
Solution Approach 1:
The patent changes the delivery parameter from oral to parenteral administration, which fundamentally alters the pharmacokinetic profile. This enables achieving therapeutic blood concentrations with much lower total drug doses, thereby reducing toxicity and side effects while maintaining reliable therapeutic effectiveness
Data Source
AI summary
Provided herein are the long-acting injection compositions of β3 adrenoreceptor agonists like mirabegron or their pharmaceutically acceptable salts or esters thereof. The present invention also relates to methods for preparing long-acting injection compositions and methods of using these dosage forms for the treatment of obesity, metabolic diseases, and other diseases as described herein. The long-acting injection compositions as per the present invention have desirable pharmaceutical technical attributes.